OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator. This document is also available as Markdown.

2025-03-31-accounts

Registered number: 3438264 Charity number: 1066856

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY

(A company limited by guarantee)

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

CONTENTS

Page
Reference and administrative details of the company, its Trustees and advisers 1 - 2
Trustees' report 3 - 7
Independent examiner's report 8
Statement of financial activities 9
Income and expenditure account 10
Balance sheet 11 - 12
Notes to the financial statements 13 - 21

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 MARCH 2025

Trustees Andrea Pokorna, Czech Republic -President (appointed 26 September 2017) Tom O'Connor, President elect (appointed 23 September 2021)

Jane Nixon, UK - Co-Treasurer and Co-Chair Guidelines Committee (appointed 23 September 2021) Dominique Sigaudo-Roussel, Co-Chair of Scientific Committee (appointed 14 September 2023) Pierre-Yves Rohan, France - Co-Chair EPUAP Research Committee (appointed 23 September 2021) Steven Smet, Belgium - Chair EPUAP Education Committee (appointed 15 September 2022) Beata Gress Halasz, Slovakia - Co-Chair EPUAP Education Commitee (appointed 25 September 2020) Lucie Charbonneau, Switzerland - Chair Annual Meeting (appointed 19 September 2019) Jan Kottner, Germany (resigned 24 September 2025)

Allison Porter Armstrong, UK -Treasurer (appointed 26 September 2017, resigned 24 September 2025) Dinitri Beeckman, Belgium (appointed 26 September 2017, resigned 24 September 2024)

Britt Hansen, Denmark (appointed 11 September 2018, resigned 24 September 2024) Katrin Balzer, Germany (appointed 14 September 2023) Rosemarie Derwin, Ireland (appointed 14 September 2023) Guido Ciprandi, Italy (appointed 1 September 2011) Ingebjorg Irgens, Norway (appointed 14 September 2023) Joan-Enric Torra i Bou, Spain (appointed 25 September 2020) Kirsti Ahmajaarvi, Finland (appointed 25 September 2020) Ulrika Kallmann, Sweden (appointed 14 September 2023) Helen Strapp, Ireland (appointed 25 September 2020) Camilla Leerskov Soerensen, Denmark (appointed 25 September 2020) Maarit Ahtiala, Finland (appointed 23 September 2021) Carina Baath, Sweden (appointed 23 September 2021) Daphne Weihs, Israel (appointed 14 September 2023) Knaerke Soegaard, Denmark (appointed 23 September 2021) Silvia Caggiari, British (appointed 24 September 2024) Susanne Colemen, British (appointed 24 September 2024) Pedro Sardo, Portuguese (appointed 24 September 2024) Peter Worsley, British (appointed 24 September 2024)

Page 1

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

Company registered
number 3438264
Charity registered
number 1066856
Registered office Clinical Trials Research Unit
University of Leeds
Leeds
West Yorkshire
LS2 9JT
Chief executive officer Andrea Pokorna
Accountants Birgitte Toft Accountancy Limited
Accountants
29 Tweedy Street
Wilsden
Bradford
West Yorkshire
BD15 0AE
Bankers Natwest Bank
Keighley (A) Branch
63 North Street
Keighley
West Yorkshire
BD21 3SB

Page 2

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY

(A company limited by guarantee)

TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2025

The Trustees present their annual report together with the financial statements of the European Pressure Ulcer Advisory Panel Charity for the year 1 April 2024 to 31 March 2025. The Annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the Annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Since the company qualifies as small under section 382 of the Companies Act 2006, the Strategic report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

Objectives and activities

a. Policies and objectives

The European Pressure Ulcer Advisory Panel (EPUAP) exists to improve the lives of people who are at risk of or suffering from pressure ulcers. Our mission is to advance research, provide public education, and influence healthcare policy across Europe to ensure patient-centered, cost-effective prevention and treatment..

EPUAP serves as a collaborative platform for clinicians, researchers, educators, policymakers, industry, lay carers and the public.Our core activities include:

Delivering EU-wide educational campaigns and resources for both clinicians and the public

Supporting cross-border interdisciplinary research

Developing and disseminating international clinical guidelines

The 3rd Edition of the Clinical Practice Guidelines , co-published with NPIAP and PPPIA in 2019, continues to be widely used worldwide. The guidelines have been translated into 19 languages, with over 6,400 downloads of the full guidelines and more than 100,000 downloads of the Quick Reference Guides. They are also available in app format to improve accessibility for healthcare professionals.

Page 3

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

Objectives and activities (continued)

b. Main activities undertaken to further the company's purposes for the public benefit

The following major meetings were organised and conducted successfully:

In 2024, EPUAP began contributing to the 4th International Pressure Injury Guideline in collaboration with NPIAP and PPPIA. The updated methodology is complete, and work on the new guidelines is progressing. The prevention chapters were released in February 2025, with treatment chapters scheduled for publication throughout 2025–2026. This will be a “live” document, continuously updated as new evidence becomes available.

EPUAP also played a key role in the Prophylactic Dressing Standards Initiative (PDSI) — a three-year programme (2021–2024) aimed at developing consensus “gold standards” for prophylactic dressings.

EPUAP remains a vibrant and growth-oriented society, raising pressure ulcer awareness, advancing education, fostering research and clinical guidelines, and engaging industry to elevate standards of care. These contributions benefit practitioners and patients as well as lay carers and wide community across Europe and beyond

c. Risk management

The trustees have identified the major risks which the charity faces and are taking steps to mitigate those risks.

Achievements and performance

a. Main achievements of the company

The 2024 Annual Meeting was held 25 - 27 September 2024 in Lausanne, Switzerland, hosted at the SwissTech Convention Center. The theme was “Pressure Ulcers – The Clock Is Ticking!”.

Awards included Innovation in Care, Investigator Awards (Early Career: Silvia Caggiari; Experienced: Jan Kottner), Excellence in Education, and various presentation awards.

The annual meeting brought together 544 participants from 44 countries. 12 key sessions, 10 free paper sessions, 7 workshops and 6 industry symposia, as well as other award sessions, were part of the scientific programme. A special issue of Journal of Wound Care was published where the best abstracts were published as well as the full text of selected invited keynote speeches.

The 2025 Annual Meeting is scheduled for 24–26 September 2025 in Helsinki, Finland .

The main theme is Care pathways in prevention and management of pressure ulcers . More information is available on the conference website: https://epuap2025.org/

Page 4

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY

(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

Achievements and performance (continued)

b. EPUAP President's vision for 2024-2025

The President’s priorities for the period focused on: Strengthening the connection between education, clinical practice, and research Supporting inter-, multi-, and transdisciplinary collaboration in pressure ulcer management Facilitating implementation of international and national-level strategies.

The Board works collectively to deliver on the President’s vision and to advance the charity’s strategy. Activities are coordinated through four committees — Research, Education, Scientific, and Guidelines — each chaired or co-chaired by Trustees who serve on a voluntary basis.

c. Review of activities

The EPUAP is a thriving society, which is constantly growing in size and influence, and will continue to expand and increase its impact related to the awareness to pressure ulcers, education, research and clinical guidelines, as well as involvement of industry – which sets higher standards for patient management and care. We will continue to lead in all the above aspects across Europe.

Page 5

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY

(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

Achievements and performance (continued)

d. Fundraising activities and income generation

EPUAP continues to strengthen its impact by supporting research, raising awareness, and encouraging collaboration.

The annual Stop Pressure Ulcer Day remains a vibrant global initiative, observed on the third Thursday of November. The 2024 event was held on 21 November, with the 2025 campaign scheduled for 20 November.

EPUAP also funds research collaborations and exchange scholarships. Projects funded during this reporting period include:

Empowering Patient Expertise (EmpowerPEx): Establishing an advisory panel to identify research priorities for pressure ulcer prevention based on lived experience

Digital PI-GAME : Evaluating the impact of a digital learning tool on nursing students’ ability to categorize and stage pressure injuries

ASPECT : Studying soft tissue properties in high-risk populations to improve prevention strategies

Financial review

a. Going concern

After making appropriate enquiries, the Trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies.

b. Reserves policy

The charity reported net outgoing resources of £27,601 for the year 2025 (2024: £32,348). The funds of the charity are continually monitored by the trustees.

It is a financial imperative of the charity to maintain unrestricted funds, which are the free reserves of the charity, at a level which equates to approximately six months unrestricted expenditure. This provides sufficient funds to cover management and administration and support costs and cover publication expenses.

This report has been prepared in accordance with the provisions of section 419(2) of the Companies Act 2006 relating to small companies.

Structure, governance and management

a. Constitution

European Pressure Ulcer Advisory Panel Charity is registered as a charitable company limited by guarantee and was set up by a Memorandum of Association.

Page 6

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

Structure, governance and management (continued)

b. Methods of appointment or election of Trustees

The management of the company is the responsibility of the Trustees who are elected and co-opted under the terms of the Memorandum of Association.

c. Financial risk management

The Trustees have identified the major risks which the charity faces and are taking steps to mitigate those risks.

Statement of Trustees' responsibilities

The Trustees (who are also the directors of the company for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 25 September 2025 and signed on their behalf by:

Andrea Pokorna

Page 7

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 MARCH 2025

Independent examiner's report to the Trustees of European Pressure Ulcer Advisory Panel Charity ('the company')

I report to the charity Trustees on my examination of the accounts of the company for the year ended 31 March 2025.

Responsibilities and basis of report

As the Trustees of the company (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the company's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

  1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or

  4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the company's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the company and the company's Trustees as a body, for my work or for this report.

Signed: Dated: 25 September 2025

Birgitte Toft Accountancy Limited MAAT MATT

Page 8

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY

(A company limited by guarantee)

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

Note
Income from:
Donations and legacies
2
Other trading activities
3
Total income
Expenditure on:
Charitable activities
4
Total expenditure
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Net movement in funds
Total funds carried forward
Unrestricted
funds
2025
£
31,506
31,163
62,669
90,120
90,120
(27,451)
272,525
(27,451)
245,074
Total
funds
2025
£
31,506
31,163
62,669
90,120
90,120
(27,451)
272,525
(27,451)
245,074
Total
funds
2024
£
38,837
48,848
87,685
121,428
121,428
(33,743)
306,268
(33,743)
272,525

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 13 to 21 form part of these financial statements.

Page 9

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

SUMMARY INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 MARCH 2025

Note
Gross income in the reporting period
Less: Total expenditure
Net expenditure for the reporting period
Total funds
2025
£
62,669
(90,120)
(27,451)
Total funds
2024
£
87,685
(121,428)
(33,743)

The notes on pages 13 to 21 form part of these financial statements.

Page 10

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee) REGISTERED NUMBER: 3438264

BALANCE SHEET AS AT 31 MARCH 2025

Note
Fixed assets
Current assets
Debtors
8
Cash at bank and in hand
Creditors: amounts falling due within one
year
9
Net current assets
Total assets less current liabilities
Net assets excluding pension asset
Total net assets
Charity funds
Restricted funds
11
Unrestricted funds
11
Total funds
(58,172)
306,382
248,210
(3,136)
2025
£
-
245,074
245,074
245,074
245,074
-
245,074
245,074
(35,814)
311,475
275,661
(3,136)
2024
£
-
272,525
272,525
272,525
272,525
-
272,525
272,525

The company was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees on 25 September 2025 and signed on their behalf by:

Page 11

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee) REGISTERED NUMBER: 3438264

BALANCE SHEET (CONTINUED) AS AT 31 MARCH 2025

Andrea Pokorna

The notes on pages 13 to 21 form part of these financial statements.

Page 12

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1. Accounting policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

European Pressure Ulcer Advisory Panel Charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

1.2 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

1.3 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the company's objectives, as well as any associated support costs.

All expenditure is inclusive of irrecoverable VAT.

1.4 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.5 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Page 13

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1. Accounting policies (continued)

1.6 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

1.7 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.8 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

2. Income from donations and legacies

Unrestricted
funds
2025
£
Sponsorships
31,506
Unrestricted
funds
2024
£
Sponsorships
38,837
Total
funds
2025
£
31,506
Total
funds
2024
£
38,837

Page 14

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

3. Income from other trading activities

Income from fundraising events

Unrestricted
funds
2025
£
Membership
4,414
Conference & Events
26,749
31,163
Unrestricted
funds
2024
£
Membership
2,648
Conference & Events
46,200
48,848
Total
funds
2025
£
4,414
26,749
31,163
Total
funds
2024
£
2,648
46,200
48,848

4. Analysis of expenditure on charitable activities

Summary by fund type

==> picture [8 x 12] intentionally omitted <==

Unrestricted
funds Total
2025 2025
£ £
Pressure ulcer relief advice 72,343 72,343
Research 17,776 17,776
Other 1 1

Page 15

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

4. Analysis of expenditure on charitable activities (continued)

Summary by fund type (continued)

Pressure ulcer relief advice
Research
Unrestricted
funds
2024
£
100,803
20,625
121,428
Total
2024
£
100,803
20,625
121,428

5. Analysis of expenditure by activities

Pressure ulcer relief advice
Research
Pressure ulcer relief advice
Research
Activities
undertaken
directly
2025
£
22,771
17,776
40,547
Activities
undertaken
directly
2024
£
54,142
20,624
74,766
Support
costs
2025
£
49,572
-
49,572
Support
costs
2024
£
46,662
-
46,662
Total
funds
2025
£
72,343
17,776
90,120
Total
funds
2024
£
100,804
20,624
121,428

Page 16

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

6. Independent examiner's remuneration

2025 2024
£ £
Fees payable to the company's independent examiner for the independent
examination of the company's annual accounts 1,740 1,740

7. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL) .

During the year ended 31 March 2025, expenses totalling £ 4,078 were reimbursed or paid directly to 26 Trustees (2024 - £3,180 to 26 Trustees) . Expenses consist of meeting and travel expenses.

8. Debtors

Due after more than one year
Other debtors
Due within one year
Trade debtors
Other unallocated
Creditors: Amounts falling due within one year
Accruals and deferred income
Other unallocated
2025
£
8,463
8,463
(66,634)
-
(58,171)
2025
£
3,136
-
2024
£
3,369
3,369
(39,183)
-
(35,814)
2024
£
3,136
-

9. Creditors: Amounts falling due within one year

Page 17

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

10. Financial instruments

2025 2024
£ £
Financial assets
Financial assets measured at fair value through income and expenditure 306,381 311,475

Financial assets measured at fair value through income and expenditure comprise of cash and bank.

Page 18

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

11. Statement of funds Statement of funds - current year

Unrestricted funds
General Funds - all funds
Unallocated amounts
Balance at 1
April 2024
£
272,525
-
272,525
Income
£
62,669
-
62,669
Expenditure
£
(90,270)
150
(90,120)
Balance at
31 March
2025
£
244,924
150
245,074

Page 19

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

11. Statement of funds (continued)

Statement of funds - prior year

Balance at
Balance at 31 March
1 April 2023 Income Expenditure 2024
£ £ £ £
Unrestricted funds
Designated Funds - all funds 306,268 87,685 (121,428) 272,525

12. Summary of funds Summary of funds - current year

General funds
Summary of funds - prior year
Designated funds
Balance at 1
April 2024
£
272,525
Balance at
1 April 2023
£
306,268
Income
£
62,669
Income
£
87,685
Expenditure
£
(90,120)
Expenditure
£
(121,428)
Balance at
31 March
2025
£
245,074
Balance at
31 March
2024
£
272,525

Page 20

EUROPEAN PRESSURE ULCER ADVISORY PANEL CHARITY (A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

13. Analysis of net assets between funds

Analysis of net assets between funds - current year

Unrestricted
funds
2025
£
Debtors due after more than one year
8,463
Current assets
239,747
Creditors due within one year
(3,136)
Total
245,074
Total
funds
2025
£
8,463
239,747
(3,136)
245,074

Analysis of net assets between funds - prior year

Debtors due after more than one year
Current assets
Creditors due within one year
Total
Unrestricted
funds
2024
£
3,369
272,291
(3,136)
272,524
Total
funds
2024
£
3,369
272,291
(3,136)
272,524

Page 21